1,000 reports of this reaction
5.1% of all GLYCOPYRROLATE reports
#1 most reported adverse reaction
DYSPNOEA is the #1 most commonly reported adverse reaction for GLYCOPYRROLATE, manufactured by Merz Pharmaceuticals, LLC. There are 1,000 FDA adverse event reports linking GLYCOPYRROLATE to DYSPNOEA. This represents approximately 5.1% of all 19,591 adverse event reports for this drug.
Patients taking GLYCOPYRROLATE who experience dyspnoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSPNOEA is moderately reported among GLYCOPYRROLATE users, representing a notable but not dominant share of adverse events.
In addition to dyspnoea, the following adverse reactions have been reported for GLYCOPYRROLATE:
The following drugs have also been linked to dyspnoea in FDA adverse event reports:
DYSPNOEA has been reported as an adverse event in 1,000 FDA reports for GLYCOPYRROLATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSPNOEA accounts for approximately 5.1% of all adverse event reports for GLYCOPYRROLATE, making it one of the most commonly reported side effect.
If you experience dyspnoea while taking GLYCOPYRROLATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.